<DOC>
	<DOCNO>NCT00016874</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine 3-AP , cisplatin , paclitaxel treat patient advanced metastatic cancer .</brief_summary>
	<brief_title>3-AP Plus Cisplatin Paclitaxel Treating Patients With Advanced Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety tolerability 3-AP , cisplatin , paclitaxel patient advance metastatic cancer . - Determine toxic effect regimen patient . - Determine maximum tolerate dose recommended phase II dose regimen patient . - Determine pharmacokinetic parameter regimen patient . - Determine tumor response patient treat regimen . OUTLINE : This dose-escalation study . Patients receive 3-AP IV continuously 96 hour day 1-4 paclitaxel IV 3 hour follow cisplatin IV 1 hour day 3 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 1 additional course therapy document CR . Patients partial response stable disease may receive therapy 6 month . Cohorts 1-6 patient receive escalate dos 3-AP , paclitaxel , cisplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 25-30 patient accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm progressive advanced metastatic cancer Failed 1 prior standard therapy disease OR Unlikely respond currently available therapy Measurable evaluable disease No active CNS metastases Previously treat CNS metastasis allow evidence new CNS metastases stable least 2 month PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : More 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL ( transfusion allow ) No active bleeding coagulation disorder ( occult blood gastrointestinal cancer allow ) Hepatic : Bilirubin great 1.5 mg/dL ALT/AST great 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Alkaline phosphatase great 3 time ULN ( 5 time ULN liver metastasis present ) Albumin least 3.0 g/dL PT/PTT great 1.5 time ULN Renal : Creatinine great 1.5 mg/dL Cardiovascular : No active heart disease No myocardial infarction within past 3 month No symptomatic coronary artery disease , heart block , uncontrolled congestive heart failure Pulmonary : No moderate severe compromise pulmonary function Other : No mental deficit and/or psychiatric history would preclude study No active infection No preexisting severe hear impairment No preexisting grade 2 great neuropathy No prior severe allergic reaction study drug No lifethreatening illness No chronic toxic effect prior chemotherapy great grade I Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 18 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Concurrent hematopoietic growth factor allow except use prophylactically first course study therapy Chemotherapy : More 3 week since prior chemotherapy ( 6 week nitrosourea mitomycin ) recover More 6 month since prior combination cisplatin paclitaxel Prior cisplatin paclitaxel single agent allow Prior 3AP allow Endocrine therapy : Not specify Radiotherapy : More 3 week since prior radiotherapy recover Concurrent radiotherapy single site progressive disease allow site require treatment within first course study therapy Surgery : Not specify Other : More 3 week since therapy malignancy recover No concurrent investigational drug without consent sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>